D-1164-2022 Class II Terminated

Recalled by Macleods Pharma Usa Inc — Plainsboro, NJ

FDA drug recall D-1164-2022 was initiated by Macleods Pharma Usa Inc on Jun 10, 2022 and is designated Class II. Reason for recall: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits The recall status is terminated (terminated May 23, 2024). Affected quantity: 84/1000 count bottles.

Recall details

Product Type
Drugs
Report Date
Jul 6, 2022
Initiation Date
Jun 10, 2022
Termination Date
May 23, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
84/1000 count bottles

Product description

Losartan potassium & Hydrochlorothiazide Tablets 100 mg/25 mg, 30, 90 & 1000 count NDC # 33342-052-07, NDC #33342-052-10 & NDC # 33342-052-44, Rx Only, MFR: Macleods Pharma USA, Inc. Plainsboro, NJ 08536

Reason for recall

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Distribution pattern

Product was distributed nationwide.

Code information

Lot # BLM2114A, exp. date 07/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1164-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1164-2022. Report a data issue: hello@regdatalab.com.